Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
November 3, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Stock Code: 600276 Stock abbreviation : Hengrui Pharma No.: Lin 2026-168

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement on the Resolution of the Sixth Meeting of the Tenth Session of the Board of Directors

The board of directors (the "**Directors**") of the Company (the "**Board**") and all Directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") convened the sixth meeting of the tenth session of the Board via teleconference on November 3, 2026. 11 Directors were required to attend this meeting, all 11 were present. The meeting was held in compliance with the Company Law of the People's Republic of China and the Articles of Association of the Company. All Directors carefully considered and approved the "Proposal on the Nomination and Appointment of the Senior Vice President of the Company".

In light of the Company's operational and development needs, Mr. Zhang Wei is hereby nominated and appointed as the senior vice president of the Company with a term commencing upon approval at this Board meeting and concluding upon the expiration of the term of the current session of the Board. The biographical details of Mr. Zhang Wei are as follows:

Zhang Wei is a seasoned pharmaceutical executive with more than 20 years of global drug development leadership experience. He brings deep expertise in clinical development, regulatory strategy, organizational leadership, and talent development across major international markets.

Prior to joining Hengrui, Zhang Wei served as Senior Vice President and Head of Medicine for Greater China at Boehringer Ingelheim. During his career, he held several

key positions in the U.S., Germany, and China, leading organizations of more than 800 employees.

With training in both medicine and biostatistics, Zhang Wei has played an instrumental role in advancing the science and practice of innovative drug development. He was the first scientist of Chinese descent within a multinational pharmaceutical company to lead a global Biostatistics and Data Sciences organization.

Throughout his career at Boehringer, he has championed initiatives designed to strengthen China's participation in global simultaneous drug development, including the implementation of the “China IN,” “China Key,” and “China KEE” strategies. These efforts helped integrate China into global early-stage clinical development programs and increased the representation of Chinese experts on global steering committees. Under his leadership, multiple innovative medicines achieved simultaneous approvals in China and other major markets, with several first global approvals in China, significantly accelerating patient access to new therapies.

Beyond his corporate responsibilities, Zhang Wei has been actively involved in fostering China's biopharmaceutical innovation ecosystem. He currently serves as Co-Chair of the China Advisory Council of the Drug Information Association (DIA) and previously served as Co-Chair of the R&D Committee of the R&D-based Pharmaceutical Association Committee (RDPAC).

Zhang Wei received his bachelor's degree in Medicine from Zhejiang University School of Medicine, with a master's degree in Medicine from Peking University Health Science Center, and a Ph.D. in Biostatistics from the University of Iowa, USA.

For: 11 votes Against: 0 votes Abstentions: 0 votes

This proposal had been considered and approved by the nomination committee of the Board.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

November 3, 2026